Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multicentre, Open, Randomised, Dose Ranging Study to Investigate the Efficacy of Combination Therapy Containing Dacarbazine (DTIC) Plus Low Dose Interferon Alpha (aIFN) Plus Thymosin a1 Versus Both DTIC Plus Thymosin a1 and DTIC Plus aIFN in Patients With Advanced -Stage Metastatic Malignant Melanoma

NCT00911443 is registered in ClinicalTrials.gov with sigma-tau i.f.r. S.p.A. as lead sponsor.

NCT NCT00911443
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00911443 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multicentre, Open, Randomised, Dose Ranging Study to Investigate the Efficacy of Combination Therapy Containing Dacarbazine (DTIC) Plus Low Dose Interferon Alpha (aIFN) Plus Thymosin a1 Versus Both DTIC Plus Thymosin a1 and DTIC Plus aIFN in Patients With Advanced -Stage Metastatic Malignant Melanoma
Lead sponsor
sigma-tau i.f.r. S.p.A.
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2002
Completion date
September 30, 2007
Enrollment
488 (actual)
Sites
64

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma